Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.
Healthpeak Properties (DOC) has been drawing attention after recent share price moves, with the stock showing double digit total returns over the past year and over the past 3 months, alongside mixed annual revenue and net income trends.
See our latest analysis for Healthpeak Properties.
The current US$19.66 share price sits against a backdrop of strong recent momentum, with a 30 day share price return of 14.97% and a year to date gain of 21.36%, while the 5 year total shareholder return shows a decline of 22.76%.
If Healthpeak Properties has you thinking about where else to find potential opportunities in real estate linked growth, it could be worth reviewing 20 top founder-led companies
With the share price near US$19.66, mixed revenue and net income trends, and a stated 40.30% intrinsic discount, the key question is whether Healthpeak Properties still trades below its fundamentals or if the market is already pricing in future growth.
Most Popular Narrative: 2.5% Undervalued
Healthpeak Properties’ most followed narrative points to a fair value of about $20.17 per share, only slightly above the recent $19.66 close, which keeps the focus firmly on the assumptions behind that estimate rather than any big gap to the market price.
Recent enhancements in drug pricing regulation and favorable U.S. tax treatment for R&D and manufacturing are bolstering domestic biopharma investment, which, together with early signs of revived funding and M&A activity in the sector, is likely to improve leasing momentum and reduce credit risk in Healthpeak’s life sciences portfolio, positively impacting both rental revenues and minimizing credit related margin pressures.
The fair value hinges on a tight set of forecasts: revenue climbing at a measured pace, margins edging higher, and a future earnings multiple that assumes investors stay comfortable paying up for this profile. The tension between modest top line assumptions and a rich implied valuation multiple is where the story really gets interesting.
Result: Fair Value of $20.17 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, that story can easily break if tenant credit issues in the lab portfolio deepen, or if capital markets stay tight and refinancing costs keep pressure on earnings.
Find out about the key risks to this Healthpeak Properties narrative.
Another Angle On Valuation
While the narrative points to a modest 2.5% gap between fair value of about $20.17 and the $19.66 share price, the current P/E of 61.2x tells a different story. That multiple is well above peers at 44x, the global Health Care REITs average at 23.4x, and the fair ratio of 28.7x. This suggests the market could shift toward a much lower earnings multiple over time. For you, that raises a simple question: is the price reflecting optimism about future cash flows or just leaving less room for error?
See what the numbers say about this price — find out in our valuation breakdown.
NYSE:DOC P/E Ratio as at May 2026 Next Steps
If this mix of optimism and concern feels familiar, do not wait on others to decide the story for you. Weigh both sides and review the 1 key reward and 4 important warning signs
Looking for more investment ideas?
Do not stop with one stock. The screener can help you surface fresh ideas quickly so you always have a watchlist ready before the next move.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include DOC.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com